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Background
Given the lack of compelling evidence supporting the use 
of antipsychotics for delirium in critically ill patients and 
the potential adverse eﬀ   ects associated with these 
medica  tions, placebo-controlled clinical trials are greatly 
needed.
Methods
Objective: To demonstrate the feasibility of a placebo-
controlled trial of antipsychotics for delirium in the 
inten  sive care unit and to test the hypothesis that 
antipsychotics would improve days alive without delirium 
or coma.
Design:  Randomized, double-blind, placebo-controlled 
trial.
Setting: Six tertiary care medical centers in the US.
Subjects: One hundred one mechanically ventilated 
medical and surgical intensive care unit patients.
Intervention: Patients were randomly assigned to receive 
haloperidol or ziprasidone or placebo every 6 hrs for up 
to 14 days. Twice each day, frequency of study drug 
administration was adjusted according to delirium status, 
level of sedation, and side eﬀ  ects.
Outcomes: Th  e primary end point was the number of 
days patients were alive without delirium or coma. 
Secondary eﬃ     cacy end points included daily delirium 
risk, duration of delirium, duration of coma, the number 
of days patients were alive and breathing without 
assistance during the 21-day study period (ventilator-free 
days), time to ICU and hospital discharge, and all-cause 
21-day survival.
Results
During the 21-day study period, patients in the 
haloperidol group spent a similar number days alive 
without delirium or coma (median [interquartile range], 
14.0 [6.0–18.0] days) as did patients in the ziprasidone 
(15.0 [9.1–18.0] days) and placebo groups (12.5 [1.2–
17.2] days; p = 0.66). No diﬀ  erences were found in secon-
dary clinical outcomes, including ventilator-free days 
(p = .25), hospital length of stay (p = .68), and mortality 
(p = .81). Ten (29%) patients in the haloperidol group 
reported symptoms consistent with akathisia, compared 
with six (20%) patients in the ziprasidone group and 
seven (19%) patients in the placebo group (p = .60), and a 
global measure of extrapyramidal symptoms was similar 
between treatment groups (p = .46).
Conclusions
A randomized, placebo-controlled trial of antipsychotics 
for delirium in mechanically ventilated intensive care 
unit patients is feasible. Treatment with antipsychotics in 
this limited pilot trial did not improve the number of 
days alive without delirium or coma, nor did it increase 
adverse outcomes. Th  us, a large trial is needed to 
determine whether use of antipsychotics for intensive 
care unit delirium is appropriate.
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Methods
Objective: To compare the eﬃ   cacy and safety of scheduled 
quetiapine to placebo for the treatment of delirium in 
critically ill patients requiring as-needed haloperidol.
Design: Prospective, randomized, double-blind, placebo-
controlled study.
Setting: Th  ree academic medical centers in the US and 
Canada.
Subjects: Th   irty-six adult intensive care unit patients with 
delirium (Intensive Care Delirium Screening Checklist 
score >=4), tolerating enteral nutrition, and without a 
complicating neurologic condition.
Intervention: Patients were randomized to receive 
quetiapine 50 mg every 12 hrs or placebo. Quetiapine 
was increased every 24 hrs (50 to 100 to 150 to 200 mg 
every 12 hrs) if more than one dose of haloperidol was 
given in the previous 24 hrs. Study drug was continued 
until the intensive care unit team discontinued it because 
of delirium resolution, therapy >=10 days, or intensive 
care unit discharge.
Outcomes: Th   e primary end point was time to ﬁ  rst reso  lu-
tion of delirium. Secondary outcomes included dura  tion of 
mechanical ventilation, ICU and hospital length of stay, 
hospital mortality, and discharge disposition. Measures of 
safety included total number of adverse and serious adverse 
events related to study drug, incidence of extrapyramidal 
symptoms, and episodes of QTc interval prolongation.
Results
Baseline characteristics were similar between the quetia-
pine (n = 18) and placebo (n = 18) groups. Quetiapine was 
associated with a shorter time to ﬁ   rst resolution of 
delirium [1.0 (interquartile range [IQR], 0.5–3.0) vs. 
4.5 days (IQR, 2.0–7.0; p =.001)], a reduced duration of 
delirium [36 (IQR, 12–87) vs. 120 hrs (IQR, 60–195; 
p  =.006)], and less agitation (Sedation-Agitation Scale 
score >=5) [6 (IQR, 0–38) vs. 36 hrs (IQR, 11–66; p =.02)]. 
Whereas mortality (11% quetiapine vs. 17%) and intensive 
care unit length of stay (16 quetiapine vs. 16 days) were 
similar, subjects treated with quetiapine were more likely 
to be discharged home or to rehabilitation (89% quetiapine 
vs. 56%; p =.06). Subjects treated with quetiapine required 
fewer days of as-needed haloperidol [3 [(IQR, 2–4)] vs. 
4 days (IQR, 3–8; p = .05)]. Whereas the incidence of QTc 
prolongation and extrapyramidal symptoms was similar 
between groups, more somnolence was observed with 
quetiapine (22% vs. 11%; p = .66).
Conclusions
Quetiapine added to as-needed haloperidol results in 
faster delirium resolution, less agitation, and a greater 
rate of transfer to home or rehabilitation. Future studies 
should evaluate the eﬀ   ect of quetiapine on mortality, 
resource utilization, post-intensive care unit cognition, 
and dependency after discharge in a broader group of 
patients.
Commentary
Delirium is an acute disturbance in consciousness and 
cognition that ﬂ  uctuates in severity. Rather than a passing 
phase, delirium is now recognized as acute brain 
dysfunction and is associated with increased length of 
stay, cost, and mortality. Delirium is very common in the 
intensive care unit (ICU), occurring in 20-80% of patients, 
with the highest proportions seen in mechanically 
ventilated patients. Th  ere is no US Food and Drug 
Administration approved treatment for delirium, though 
national guidelines recommended haloperidol as the 
drug of choice [3]. More recently, atypical antipsychotics 
have also been used. Observational data and one small 
randomized controlled trial in patients with hip fracture 
suggest improved outcomes with antipsychotics [4,5], yet 
until recently there were no placebo-controlled clinical 
trials in ICU patients to determine whether these drugs 
improve clinical outcomes or merely treat symptoms.
Th   e two pilot studies reviewed in this critique provide 
the ﬁ  rst randomized, placebo-controlled evidence for the 
pharmacologic treatment of ICU delirium [1,2]. In the 
ﬁ  rst study, Girard and colleagues compared haloperidol, 
ziprasidone, and placebo in the treatment of delirium in 
101 adult mechanically ventilated medical and surgical 
ICU patients [1]. Twice daily the frequency of study drug 
administration was adjusted according to delirium status 
and side eﬀ  ects. Th  e authors found that neither halo-
peridol nor ziprasidone signiﬁ  cantly reduced the dura-
tion of delirium compared with placebo. No diﬀ  erences 
were found in secondary clinical outcomes, including 
ventilator-free days, hospital length of stay and mortality. 
Th  e adverse events were similar between the three 
groups with no events being serious. Ten patients had 
prolongation of the QTc >500 msec (haloperidol 5.7% vs. 
ziprasidone 16.7% vs. placebo 8.3%, p=0.31), usually 
within 48 hours of study drug initiation.
In the second study, Devlin and colleagues compared 
quetiapine and placebo in the treatment of delirium in 36 
adult medical and surgical ICU patients [2]. In this study, 
quetiapine was increased every 24 hours if more than one 
dose of haloperidol was given in the previous 24 hours. 
Th   e authors found that scheduled, dose-escalated quetia-
pine added to as-needed haloperidol resulted in faster 
delirium resolution, less agitation, and a trend toward a 
greater rate of transfer to home or rehabilitation without 
any diﬀ  erences in mortality. Th   ere were no serious study 
drug-related adverse events. QTc prolongation 
>500 msec was more common in placebo subjects (28% 
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(p=1.0).
Th  ese two studies are groundbreaking in the area of 
ICU delirium. Both were well-conducted and used 
validated and reliable delirium screening tools. In neither 
study were serious adverse events more common in 
active treatment groups, suggesting that antipsychotics 
were safe, at least within these patient populations and 
within the context of close monitoring for adverse events. 
Unfortunately, both studies were too small to reliably 
detect diﬀ  erences in important clinical outcomes, such as 
mortality or length of stay. Th  is limitation was further 
ampliﬁ  ed by the use of open-label, as-needed anti  psy-
chotics if the clinical team considered it necessary, thereby 
minimizing potential diﬀ  erences between groups.
When encountering delirium in the ICU, it is important 
to start with modiﬁ  able risk factors, such avoiding poly-
pharmacy, promoting sleep hygiene, correcting electro-
lyte abnormalities, and reorienting frequently, before 
reaching for drugs. Practically speaking, non-pharma-
cologic interventions are frequently insuﬃ   cient.  In 
addition to antipsychotics, emerging research suggests 
that alternative sedative agents, such as dexmedetomidine 
[6,7], may be less prone to causing delirium. Furthermore, 
daily sedation interruption and early physical therapy 
may also be beneﬁ  cial [8].
Recommendation
Taken together, the result of these pilot studies highlight 
the need for much larger, multicenter, placebo-controlled 
trials to determine whether continued use of anti-
psychotics in the ICU is warranted. Th   ough screening for 
delirium using a validated instrument and treating with 
haloperidol remain recommended by national guidelines, 
clinicians should routinely monitor for adverse events, 
especially QTc prolongation.
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